Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antitumor combination drug and application thereof in preparation of anti-cancer drug

An anti-cancer drug and anti-tumor technology, applied in the field of biomedicine, can solve the problems of limited curative effect, large toxic and side effects, etc.

Active Publication Date: 2017-12-01
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, BCR-ABL inhibitors have problems such as high toxicity and side effects, which make their efficacy limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antitumor combination drug and application thereof in preparation of anti-cancer drug
  • Antitumor combination drug and application thereof in preparation of anti-cancer drug
  • Antitumor combination drug and application thereof in preparation of anti-cancer drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 MTT determination of proliferation inhibition of combination medication

[0031] 1.1 Test materials

[0032] Tested drugs: chlorogenic acid, imatinib, nilotinib, dasatinib, bosutinib, panatinib.

[0033] Cell line: Chronic myeloid leukemia cell line K562, human normal hematopoietic stem cell HSPC-1

[0034] 1.2 Test method

[0035] Inoculate 100μl of cells on 96-well culture plate under aseptic conditions, the number of inoculated cells is 5×l0 3 / hole. Cells at 37℃, 5% CO 2 Incubate in the incubator, and the cells are divided into: blank control group, negative control group, single medication group, chlorogenic acid group and combined medication group. The blank control group is not inoculated with cells. The total amount of culture medium and medicine in each well is 200μl, and each concentration is set up with 3 multiple holes, and an equal volume of culture medium is used as a blank control instead of medicine. Continue to set 5% CO 2 Continue culturing in a 37°...

Embodiment 2

[0053] Example 2 Chlorogenic acid reverses the resistance of human leukemia cells to dasatinib in vitro

[0054] 2.1 Materials

[0055] Tested drugs: chlorogenic acid, dasatinib

[0056] Cell line: Chronic myelogenous leukemia cell line K562 is a routinely cultured cell in the laboratory. It is passaged before use. Cells that are in a good growth state and grow in the logarithmic phase are selected for use.

[0057] 2.2 Test method

[0058] 2.2.1 Cultivation of drug-resistant cell lines

[0059] K562 cell lines were exposed to Dasatinib 100nmol / L for 3 months, and centrifuged to culture Dasatinib-resistant K562 / NY cells. Cells were observed every day and passed 1 passage 3 passages for about 3 days to ensure cell viability .

[0060] 2.2.2 Detect the IC50 of Dasatinib against cell lines and drug-resistant strains, and calculate the drug-resistant multiples

[0061] Take logarithmic growth phase K562 cells and drug-resistant cell lines, adjust the cell concentration to 8×10 3 Pieces / well w...

Embodiment 3

[0078] Example 3 Combination of chlorogenic acid and BCR-ABL small molecule inhibitors in vivo anti-tumor effect

[0079] 3.1 Materials and instruments

[0080] Tested drugs: Chlorogenic acid; Imatinib, Nilotinib, Dasatinib, Bosutinib, Panatinib

[0081] Test cell line: Chronic myeloid leukemia cell line K562

[0082] Test animal: BABL / c-nu mouse, 18-22g, female

[0083] 3.2 Test method

[0084] 3.2.1 Establishment of experimental animal tumor model

[0085] Collect the cells in logarithmic growth phase, centrifuge at 1000 rpm for 5 min, wash the cells twice with PBS, and adjust the cell concentration to 1x10 with serum-free medium after counting. 7 / m1, sent to the animal room under aseptic conditions. Under sterile experimental conditions, mice were injected subcutaneously into the right armpit of 1×10 7 / m1 cells, 0.1ml each, obvious skin hills appeared in the injection area, and a large nodules of rice grains appeared on the left axilla of nude mice one week later, indicating that th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antitumor combination drug and an application thereof in preparation of an anti-cancer drug. The antitumor combination drug is prepared from 10-40 parts by weight of a first preparation and 0.1-10 parts by weight of a second preparation. The invention further discloses an application of chlorogenic acid in preparation of a toxic and side effect inhibitor for the anti-cancer drug, and the anti-cancer drug is a BCR-ABL small-molecule inhibitor. With the adoption of the technical scheme, targeting ability of the BCR-ABL small-molecule inhibitor for chronic granulocytic leukemia can be improved, toxic and side effects of the BCR-ABL small-molecule inhibitor are reduced, and drug resistance of the BCR-ABL small-molecule inhibitor is reversed.

Description

Technical field [0001] The invention relates to the field of biomedicine, and specifically relates to an anti-tumor combination drug and its use in preparing anti-cancer drugs. Background technique [0002] Chlorogenic acid is a kind of phenylpropanoids synthesized by intermediate products of the pentose phosphate pathway in the process of plant aerobic respiration. With mature extraction and synthesis technology, chlorogenic acid has been developed and applied in many fields such as food, health products, cosmetics and medicines. The current research results show that chlorogenic acid has the effects of protecting cardiovascular, anti-oxidation, anti-ultraviolet, anti-radiation, anti-cancer, anti-bacterial, anti-viral and immune regulation. [0003] Leukemia is a common type of hematopoietic malignant tumor that seriously threatens human health. In my country, the annual incidence of leukemia is 300,000-400,000, ranking seventh among adult malignant tumors and first among childr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/216A61K31/506A61K31/5025A61K31/496A61P35/00A61P35/02
CPCA61K31/216A61K31/496A61K31/5025A61K31/506A61K45/06A61K2300/00
Inventor 张洁黄望杨华蓉张梦甜
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com